Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (7)
Type
Type
Guidance (373)
NICE advice (1)
Quality standard (9)
Guidance programme
Guidance programme
Clinical guidelines (27)
Diagnostics guidance (9)
Health technology evaluations (11)
Highly specialised technologies guidance (8)
Interventional procedures guidance (10)
Medical technologies guidance (11)
NICE guidelines (30)
Public health guidelines (1)
Technology appraisal guidance (302)
Advice programme
Advice programme
Medtech innovation briefings (1)
Apply filters
Showing 301 to 350 of 383
Sort by
Title
Date
Apply sorting
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Review of TA611) [ID4069]
Technology appraisal guidance
12 June 2024
Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID6377]
Technology appraisal guidance
TBC
Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]
Technology appraisal guidance
TBC
Ruxolitinib for treating non-segmental vitiligo in people 12 years and over [ID3998]
Technology appraisal guidance
31 July 2024
Sacituzumab govitecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy and a PD-1 or PD-L1 inhibitor [ID6375]
Technology appraisal guidance
TBC
Sacituzumab govitecan for treating hormone receptor-positive HER2-negative metastatic breast cancer after 2 or more therapies [ID4033]
Technology appraisal guidance
TBC
Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention
Interventional procedures guidance
TBC
School-based interventions: physical and mental health and wellbeing promotion
Quality standard
TBC
Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis [ID3738]
Technology appraisal guidance
TBC
Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma (Partial review of TA688) [ID6376]
Technology appraisal guidance
3 July 2024
Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]
Technology appraisal guidance
21 August 2024
Selpercatinib for previously treated RET fusion-positive advanced non-small-cell lung cancer (MA review of TA760) [ID6293]
Technology appraisal guidance
13 November 2024
Selpercatinib for untreated RET-positive advanced thyroid cancer [ID6183]
Technology appraisal guidance
TBC
Sipavibart for preventing COVID 19 [ID6282]
Technology appraisal guidance
26 February 2025
Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]
Technology appraisal guidance
TBC
Sodium phenylbutyrate–ursodoxicoltaurine for treating amyotrophic lateral sclerosis [ID6246]
Technology appraisal guidance
TBC
Somapacitan for treating growth hormone deficiency in children [ID6178]
Technology appraisal guidance
TBC
Sotatercept for treating pulmonary arterial hypertension [ID6163]
Technology appraisal guidance
TBC
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
Technology appraisal guidance
26 February 2025
SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)
Medical technologies guidance
TBC
Sparsentan for treating primary IgA nephropathy [ID6308]
Technology appraisal guidance
30 April 2025
Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]
Technology appraisal guidance
21 April 2021
Spesolimab for preventing generalised pustular psoriasis flares [ID6216]
Technology appraisal guidance
TBC
Spesolimab for treating acute generalised pustular psoriasis [ID3963]
Technology appraisal guidance
TBC
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
Technology appraisal guidance
9 July 2024
Sugemalimab with chemotherapy for untreated metastatic non-small-cell lung cancer [ID4001]
Technology appraisal guidance
TBC
Surgical correction of hallux valgus using minimal access techniques
Interventional procedures guidance
20 June 2024
Surgical vessel sealing systems (MT798)
Medical technologies guidance
TBC
Suspected cancer update
Quality standard
TBC
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
TBC
Suspected sepsis: recognition, diagnosis and early management
NICE guideline
13 August 2025
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]
Technology appraisal guidance
19 June 2024
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]
Technology appraisal guidance
TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]
Technology appraisal guidance
TBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
Technology appraisal guidance
11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401
Technology appraisal guidance
TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
Technology appraisal guidance
TBC
Technologies for the assessment of attention deficit hyperactivity disorder (ADHD)
Diagnostics guidance
TBC
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]
Technology appraisal guidance
14 August 2024
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]
Technology appraisal guidance
TBC
Tenecteplase for treating acute ischaemic stroke [ID6306]
Technology appraisal guidance
TBC
Third molars (impacted) - prophylactic removal [ID898]
Technology appraisal guidance
TBC
Tirzepatide for managing overweight and obesity [ID6179]
Technology appraisal guidance
19 June 2024
Tislelizumab for previously treated advanced oesophageal squamous cell cancer [ID4070]
Technology appraisal guidance
TBC
Tislelizumab for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6161]
Technology appraisal guidance
TBC
Tislelizumab in combination for untreated advanced non-small-cell lung cancer [ID6162]
Technology appraisal guidance
TBC
Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]
Technology appraisal guidance
TBC
Topical Antimicrobial dressings for wound care: Late stage assessment
Health technology evaluation
TBC
Topical rapamycin for treating facial angiofibromas associated with tuberous sclerosis complex in people 6 years and over [ID6391]
Technology appraisal guidance
TBC
Total hip arthroplasty using the superpath approach for osteoarthritis
Interventional procedures guidance
TBC
Previous page
1
…
5
6
Current page
7
8
Page
7
of
8
Next page
Results per page
10
25
50
All
Back to top